ライフサイエンスコーパス: enkephalin

1 rodynorphin) with enkephalin (or Phe-Arg-Met-enkephalin).

2 ntisera against beta-endorphin or methionine-enkephalin.

3 itters gastrin-releasing peptide and leucine-enkephalin.

4 arasympathetic) neurons and those containing enkephalin.

5 likely interact with nerve fibers containing enkephalin.

6 and specific down-regulation of the DRD2 and enkephalin.

7 otein of the active peptide neurotransmitter enkephalin.

8 stimulation by the opioid peptide methionine enkephalin.

9 mounts of nicotine-induced secretion of (Met)enkephalin.

10 hat cathepsin L in vivo was colocalized with enkephalin.

11 y residue was proved by the synthesis of Leu-enkephalin.

12 l cord, where multiple peptidases metabolize enkephalin.

13 gonist, carboxynitrobenzyl-tyrosine-[Leu(5)]-enkephalin.

14 PENK is a stable analyte of labile enkephalins.

15 g with the mu/delta selective opioid [Met(5)]enkephalin (1 mum) decreased spontaneous dopamine transi

16 In contrast, enkephalins (100-1000 nmol) and nociceptin-orphanin FQ (

17 nist, [(3)H][d-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin ([(3)H]DAMGO).

18 hesis of an azaphenylalanine analogue of Leu-enkephalin 40.

19 Extension to the syntheses of Leu-enkephalin (9) and amyloid-beta (34-42) (10) demonstrate

20 jections coexpress GABA and the neuropeptide enkephalin, a delta and mu opioid receptor (MOR) ligand.

21 critical for the hydrolysis of exogenous Leu-enkephalin, a neuropeptide present in the CA3 region of

22 Intra-PFC DAMGO (D-[Ala2,N-MePhe4, Gly-ol]-enkephalin; a mu-opioid agonist) and d-amphetamine were

23 alated cells of the amygdala as an assay for enkephalin activity, we applied specific peptidase inhib

24 effect associated with administration of the enkephalin alone.

25 totoxicity also exacerbated or prevented the enkephalin alterations.

26 nd limited receptor internalization, whereas enkephalin analogs promote robust trafficking of both be

27 Enkephalin analogues with a 4-anilidopiperidine scaffold

28 Moreover, neurons triple-labeled with c-Fos, enkephalin and 5-HT were noted frequently in the NRP fol

29 duced by EA and examined its relationship to enkephalin and 5-HT.

30 on (LOQ) by analyzing targeted peptides, leu-enkephalin and angiotensin II, spiked in a BSA tryptic d

31 ng the neuropeptides substance P, dynorphin, enkephalin and cholecystokinin.

32 ion of cathepsin L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are pre

33 s, including PSD-95, and opioid peptides leu-enkephalin and dynorphin in the hippocampus of young ani

34 age, females showed opposing changes in leu-enkephalin and dynorphin levels in the mossy fiber pathw

35 ird, we examined co-localization of Y1R with enkephalin and dynorphin neurons and the effect of NPY o

36 Both enkephalin and dynorphin partly colocalized with vesicul

37 phase- and gas-phase deuterium uptake of Leu-Enkephalin and Glu-Fibrinopeptide B, confirmed that this

38 we examined how patch output is modulated by enkephalin and identified the underlying circuit mechani

39 c-based solid-phase peptide synthesis of Leu-enkephalin and in microwave-assisted automated synthesis

40 biologically active conformation of leucine enkephalin and its methyl ester in the nonpolar cell mem

41 An equimolar mixture of leucine enkephalin and maltopentaose was studied to verify that

42 ase in the pPVN, due to increased endogenous enkephalin and mu-opioid receptor production in brainste

43 s in droplets containing bradykinin, leucine enkephalin and myoglobin, but loss of the heme group fro

44 n V protease for producing the neuropeptides enkephalin and neuropeptide Y (NPY).

45 teolytic conversion of proproteins to active enkephalin and neuropeptides.

46 Whereas CPA6 converts enkephalin and neurotensin into forms known to be inacti

47 in human brain cortex and hippocampus where enkephalin and NPY are produced and is present in purifi

48 Colocalization of cathepsin V with enkephalin and NPY in secretory vesicles of human neurob

49 function of human cathepsin V for producing enkephalin and NPY neuropeptides required for neurotrans

50 the evidence supporting cleavage at proline, enkephalin and peptide A-779, two peptides that do not c

51 2, involved in matrix remodeling, as well as enkephalin and RUNX3, potentially involved in the increa

52 In this study Tyr residues of both leucine enkephalin and salmon calcitonin (sCT) were targeted usi

53 d D3R GFP fluorescent cells colocalized with enkephalin and substance P immunoreactive medium spiny n

54 g the D1 subtype were immunopositive for met-enkephalin and vesicular glutamate transporter VGLUT2, b

55 These results show that enkephalins and dynorphins are present in different popu

56 oid peptides targeting mu-receptors, such as enkephalins and endorphins, underlying the regulation of

57 erved cell surface protease that inactivates enkephalins and other bioactive peptides.

58 s of the opioid growth factor (OGF, [Met(5)]-enkephalin) and a low dose of the opioid antagonist nalt

59 n opioid peptide ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) and a selective sodium channel (NaV1.7)-bloc

60 The opioid growth factor (OGF; [Met(5)]-enkephalin) and the OGF receptor (OGFr) form an endogeno

61 s endogenous opioids (beta-endorphin and Met-enkephalin) and uroguanylin in apical compartments close

62 levels of Kcnk5/Gpr4/pre-pro-galanin/pre-pro-enkephalin, and do not respond to hypercapnia.

63 expression of orexigenic peptides, galanin, enkephalin, and dynorphin, in the paraventricular nucleu

64 ion of the striatal dopamine receptor D2 and enkephalin, and improved procedural learning.

65 hin II, [d-Pen(2), d-pen(5)]-enkephalin, met-enkephalin, and SNC-80 ((+)-4-[(alphaR)-alpha-((2S,5R)-4

66 control pain through temporally coordinated enkephalin- and GABA-mediated presynaptic inhibition of

67 be processed by CPA6, including Met- and Leu-enkephalin, angiotensin I, and neurotensin.

68 on microscopy using substance P and Met-/Leu-enkephalin antibodies to label GABAergic terminals from

69 An anti-enkephalin antibody, which recognized Leu-, Met-, and Ph

70 lidal neurons were identified by rabbit anti-enkephalin antibody.In NT mice, PDE10A is equally expres

71 agonist, DAMGO ([d-Ala2, NMe-Phe4, Gly5-ol]-enkephalin), appeared to attenuate this negative incenti

72 the circuit elements in patches regulated by enkephalin are unclear.

73 Enkephalins are cardiodepressive and difficult to measur

74 ar to that of DAMGO, alpha-neoendorphin, Met-enkephalin-Arg-Phe, and the putatively endogenous peptid

75 Using leucine enkephalin as a diagnostic molecule, the fragmentation e

76 ndogenous peptide opioid receptor ligand Leu-enkephalin as a model compound.

77 agonist DAMGO (D-Ala2-N-Me-Phe(4)-glycol(5)-enkephalin), as shown by analysis of downstream targets

78 Met-enkephalin, but not the mu-selective (DAMGO) and delta-s

79 n SK-N-MC cells results in reduction of (Met)enkephalin by more than 80%, illustrating the prominent

80 consistent with the fact that both GABA and enkephalin can exert presynaptic inhibition of the senso

81 A leucine enkephalin-coated surface demonstrated good linearity (R

82 To enhance detection of perikarya containing enkephalin, colchicine (90-100 microg/kg) was administer

83 enhance detection of cell bodies containing enkephalin, colchicine (90-100 mug/kg) was administered

84 orexigenic neuropeptide Y, dynorphin and met-enkephalin, consistent with an anorexic role in energy h

85 dorsal horn homogenates and presynaptic met-enkephalin-containing boutons.

86 alin, resulting from the conversion of PE to enkephalin-containing intermediates of 23, 18-19, 8-9, a

87 in some medullary nuclei (e.g., raphe), only enkephalin-containing neuronal processes were found in t

88 occurs at dibasic residue sites to generate enkephalin-containing peptides and an approximately 24-k

89 orsal horn, probably from a subpopulation of enkephalin-containing presynaptic terminals.

90 eGFP-expressing neurons were associated with enkephalin-containing varicosities, and enkephalin-induc

91 trated that the DOR agonist D-[Pen(2),Pen(5)]enkephalin could induce receptor internalization and ade

92 ts beta-arrestin2, whereas the MOR-selective enkephalin [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin (D

93 saturating doses of the hydrolysis-resistant enkephalin [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAMGO).

94 ns with the DOR agonist [d-Ala(2), d-Leu(5)]-enkephalin (DADLE) caused a decrease in the membrane abu

95 decreased the potency of [D-Ala(2),D-Leu(5)]-enkephalin (DADLE), and decreased the potency and effica

96 the mu-OR agonist, D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) (0.25 mug), directly into the AcbSh o

97 The MOR agonist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) also occluded the ability of DOR agon

98 es of the opioid [d-Ala2, N-MePhe4, Gly5-ol]-enkephalin (DAMGO) and a switch in the functional effect

99 de agonists [d-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO) and endomorphin-2 activated inwardly

100 MOR with [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) and morphine and imaged in real time

101 tor agonist (D-Ala(2),N-Me-Phe(4),Gly-ol(5))-enkephalin (DAMGO) at 1 mum, but not at 1-10 nm, caused

102 ]diprenorphine and [d-Ala2,NMe-Phe4,Gly5-ol]-enkephalin (DAMGO) binding and effect of MTSEA on [3H]di

103 ]diprenorphine and [D-Ala2,NMe-Phe4,Gly5-ol]-enkephalin (DAMGO) binding and effect of MTSEA on [3H]di

104 by morphine or [d-Ala(2),N-MePhe(4), Gly-ol]enkephalin (DAMGO) causes differences in spatiotemporal

105 ne, fentanyl, and [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) induce extensive receptor phosphoryla

106 -opioid agonist [d-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO) markedly increased intake of standard

107 e morphine and D-Ala(2), N-MePhe(4), Gly-ol]-enkephalin (DAMGO) nonbiased agonists and to the TRV130

108 with either MOR [D-Ala, N-Me-Phe, Gly-ol(5)-enkephalin (DAMGO) or morphine] or DOR (D-Pen(5)-enkepha

109 the micro agonist [D-Ala2,N-MePhe4, Gly-ol5]enkephalin (DAMGO) or the alpha2 agonist clonidine inhib

110 pplication of [D-Ala(2)-N-Me-Phe(4),Gly5-ol]-Enkephalin (DAMGO), a MOR agonist, that is blocked by D-

111 nfusions of D-Ala(2), NMe-Phe(4), Gly-ol(5)]-enkephalin (DAMGO), a mu-opioid receptor agonist, in the

112 nalizing opiate, and (D-Ala2,MePhe4,Gly-ol5) enkephalin (DAMGO), a potent muOR-internalizing agonist,

113 id agonist [D-Ala(2),methyl-Phe(4),Gly(5)-ol]enkephalin (DAMGO), as demonstrated by both Western blot

114 e mu agonist, Tyr-D-Ala', N-CH, -Phe4, Glyol-Enkephalin (DAMGO), delta opioid agonists, D-pen(2), D-p

115 (Met-Enk), [d-Ala(2), N-MePhe(4), Gly-ol(5)]-enkephalin (DAMGO), endomorphin-2, and morphine in rat a

116 e enkephalin [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO), recruits either beta-arrestin.

117 opioid agonist, [d-Ala(2),N-MePhe(4),gly-ol]-enkephalin (DAMGO), to produce tolerance for its inhibit

118 id receptor agonist D-Ala2-N-Me-Phe4-gly5-ol-enkephalin (DAMGO), we demonstrate that orexin signaling

119 electivity of [D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin (DAMGO)-related glycopeptides by altering the

120 [d-Ala2,(N-Me)Phe4,Gly5-OH] enkephalin (DAMGO)-stimulated [(35)S]GTPgammaS binding w

121 by morphine and [D-Ala(2),Phe(4),Gly(5)-ol]-enkephalin (DAMGO).

122 esistant enkephalin [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAMGO).

123 ffects of the agonist d-Ala2-N-MePhe4-Gly-ol enkephalin (DAMGO).

124 mu-opioid agonist D-[Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO, 2.5 mug), then challenged with intra-

125 receptor agonist ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DAMGO) generated intense >250% increases in

126 -Phe-Ser-Arg-OH), a human peptide inhibiting enkephalin degradation, was performed.

127 e III (DPP III) is one of the most important enkephalin-degrading enzymes associated with the mammali

128 duced by morphine and RB101 (an inhibitor of enkephalin-degrading enzymes, which increases the synapt

129 or (MOR) selective agonists ([D-Pen2,D-Pen5]-Enkephalin, deltorphin II, SNC80, and DAMGO) and antagon

130 Topical application of [Met(5)]-enkephalin depressed tear secretion from baseline scores

131 es CR-triggered hypothermia and that leucine enkephalin directly controls core body temperature when

132 ), delta opioid agonists, D-pen(2), D-phe(5) enkephalin (DPDPE), and kappa agonist, U50 488, all sign

133 or-BNI) enhanced the potency of [D-Pen(2,5)]-enkephalin (DPDPE), decreased the potency of [D-Ala(2),D

134 od was used to determine met-enkephalin, leu-enkephalin, dynorphin A(1-8), and beta-endorphin in vivo

135 exigenic neuromodulators neuropeptide Y, met-enkephalin, dynorphin and the catecholamine dopamine.

136 ative peroxidase immunohistochemistry of leu-enkephalin, dynorphin, synaptophysin, and PSD-95.

137 In hAPP mice, enkephalin elevations correlated with the extent of Abet

138 We conclude that enkephalin elevations may contribute to cognitive impair

139 Enkephalins, endogenous ligands for delta opioid recepto

140 Protecting enkephalins, endogenous opioid peptides released in resp

141 NK (proenkephalin) is a stable surrogate for enkephalins, endogenous opioid peptides, which exert car

142 singly, co-injection of naloxone with either enkephalin enhanced the effect associated with administr

143 ibility that the orexigenic peptide systems, enkephalin (ENK) and orexin (OX), which are stimulated b

144 male starlings also had significantly higher enkephalin (ENK) immunolabeling densities in the POM tha

145 NT colocalization with the endogenous opioid enkephalin (ENK) in the RVM during thermal hyperalgesia,

146 ing in situ hybridization histochemistry for enkephalin (ENK) mRNA in the ventral striatum.

147 only Ucn 3 neurons in the rPFH co-expressed enkephalin (Enk), and Ucn 3/Enk double-labeled nerve fib

148 ergic synapses colocalize the opioid peptide enkephalin (ENK), but the neurons to which they belong a

149 on by gamma-aminobutyric acid (GABA) and met-enkephalin (ENK).

150 opioid peptides [e.g., proopiomelanocortin, enkephalin (ENK)] with the stress-related peptide cortic

151 well as mRNA levels of the endogenous opioid enkephalin (ENK-mRNA).

152 Enkephalins (ENKs) are endogenous opioids that regulate

153 prevented by transfection in vitro with the enkephalin-expressing vector.

154 Met/Leu-enkephalin expression was altered in pathological skin,

155 leus size, loss of dendritic spines, reduced enkephalin expression, diminished nigral dopaminergic pr

156 Here we present SID of leucine enkephalin, fibrinopeptide A, melittin, insulin chain-B,

157 SK-N-MC cells results in production of (Met)enkephalin from proenkephalin.

158 To provide insight into enkephalin function we used a chronic social defeat stre

159 These results suggest that enkephalin gates limbic information flow in dorsal stria

160 lymer nanoparticles encapsulating leucine(5)-enkephalin hydrochloride (LENK) are able to transport LE

161 ic agonist DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-Enkephalin) hyperpolarizes medially located ITCs (mITCs)

162 Enkephalin immunolabeling was detected within a single m

163 Enkephalin immunoreactivity did not colocalize with the

164 e accurate and precise quantification of Leu-enkephalin in a complex mixture using multiple-reaction

165 NL led to increased immunoreactivity for met-enkephalin in dorsal horn homogenates, which was dose-de

166 suggesting a role for the inhibitory peptide enkephalin in responses evoked by glucoprivation.

167 Mass spectroscopy confirmed Leu- and Met-enkephalin in skin.

168 Furthermore, labeling for the opioid met-enkephalin in the medial preoptic nucleus (POM) correlat

169 These data suggest that increased enkephalin in the rVLM induced by repetitive EA contribu

170 dominant peptidase responsible for degrading enkephalins in the intercalated cells of the amygdala.

171 Two series of 22 and 15 atom cyclic enkephalins incorporating a diversely substituted guanid

172 scimol reduced DAMGO (D-Ala2-NMe-Phe4-Glyol5-enkephalin)-induced and baseline food intake, whereas in

173 with enkephalin-containing varicosities, and enkephalin-induced clathrin- and dynamin-mediated endocy

174 treated animals, recovery from acute [Met](5)enkephalin-induced desensitization and receptor recyclin

175 tracellular concentrations and half-lives of enkephalins, inducing potent antinociceptive effects.

176 Neuropeptides dynorphin and met-enkephalin inhibited dopamine neurons, whereas oxytocin

177 one by blocking the enzymatic degradation of enkephalin inhibited GABA neurotransmission in yoked sal

178 trongly limited by peptidases, which degrade enkephalin into inactive fragments.

179 ist DAMGO (D-ala(2) -N-Me-Phe(4) -Glycol(5) -enkephalin) into the rostrodorsal part of the accumbens

180 Methionine-enkephalin (M-ENK) and leucine-enkephalin (L-ENK) are small endogenous opioid peptides

181 which recognized Leu-, Met-, and Phe-Arg-Met-enkephalin, labeled the dorsolateral funiculus and numer

182 phalin, which did not recognize Leu- and Met-enkephalin, labeled the same puncta.

183 activatable analogs of two opioids: [Leu(5)]-enkephalin (LE) and the 8 amino acid form of Dynorphin A

184 Within the HF, leu-enkephalin (LENK) is most prominent in the mossy fiber (

185 Leucine(5)-enkephalin (LENK) nanofibres formed from the LENK ester

186 the effect of exposure to exogenous leucine-enkephalin (Leu-Enk), methionine-enkephalin (Met-Enk), a

187 The method was used to determine met-enkephalin, leu-enkephalin, dynorphin A(1-8), and beta-e

188 nimal model of Huntington's disease in which enkephalin levels are reduced in striatum and comorbidit

189 Met-enkephalin levels in neuronal projections from the entor

190 l, with or without progesterone, altered leu-enkephalin levels in the dentate gyrus and synaptophysin

191 In human AD brains, enkephalin levels in the dentate gyrus were also increas

192 wild-type mice, Q175 animals showed reduced enkephalin levels in the NAc and enhanced susceptibility

193 controls, susceptible animals showed reduced enkephalin levels in the NAc.

194 withdrawal from cocaine self-administration enkephalin levels in the VP are elevated and the opioid

195 Such decrease in enkephalin levels is not due to a change in mRNA of its

196 In Alzheimer's disease (AD), elevated enkephalin levels may reflect compensatory processes or

197 r reserpine was shown previously to increase enkephalin levels severalfold.

198 niques that allow detection of extracellular enkephalin levels.

199 Ligand 16, in which a Dmt-substituted enkephalin-like structure was linked to the N-phenyl-N-p

200 Methionine-enkephalin (M-ENK) and leucine-enkephalin (L-ENK) are sm

201 se in CID sensitivity for protonated leucine enkephalin (m/z 556), and 14x increase of CID sensitivit

202 tance by submaximal concentrations of Met(5)-enkephalin (ME) and somatostatin (SST; coupling to nativ

203 concentration of the opioid agonist [Met(5)]-enkephalin (ME) caused significantly less desensitizatio

204 jection of opioid agonists DAMGO or [Met(5) ]enkephalin (ME) into the KF reduced respiratory frequenc

205 Activation of the FLAGMOR with [Met5]enkephalin (ME) produced a hyperpolarization that desens

206 sporine did not reduce the extent of [Met(5)]enkephalin (ME)-induced desensitization but increased th

207 tions of buprenorphine decreased the [Met](5)enkephalin (ME)-induced hyperpolarization or outward cur

208 stimulation of MOR in LC neurons with Met(5)-enkephalin (ME).

209 cysteine protease pathway for producing the enkephalin member of neuropeptides.

210 Numerous met-enkephalin (mENK) and dynorphin-immunoreactive boutons a

211 of such interactions, we exposed methionine-enkephalin (MENK) to PN and identified the major metabol

212 e (ir) for galanin, GABA, TRH, or methionine-enkephalin (mENK) were dense in the ventrocaudal hypotha

213 Met-enkephalin (mENK), an endogenous opioid, and exogenous o

214 ptor-saturating concentrations of methionine-enkephalin (Met-Enk), [d-Ala(2), N-MePhe(4), Gly-ol(5)]-

215 ous leucine-enkephalin (Leu-Enk), methionine-enkephalin (Met-Enk), and the opioid antagonist naloxone

216 nced for deltorphin II, [d-Pen(2), d-pen(5)]-enkephalin, met-enkephalin, and SNC-80 ((+)-4-[(alphaR)-

217 Moreover, Acb enkephalin neurons expressed Y1R and arcuate nucleus NPY

218 2) agonist DAMGO (D-Ala2, N-Me-Phe4, Gly5-ol-enkephalin) of the incorporation of [(35)S]-guanosine 5'

219 1H-imidazole]; the effect of vector-mediated enkephalin on Na(V)1.7 levels was prevented by naltrindo

220 e effect of transgene-mediated expression of enkephalin on pain-related behaviors and their biochemic

221 ioid peptide, opioid growth factor ([Met(5)]-enkephalin), on the onset and progression of EAE.

222 on of cathepsin L for biosynthesis of active enkephalin opioid peptide contrasts with its function in

223 In the hippocampal formation (HF), the enkephalin opioids and estrogen are each known to modula

224 neurons double-labeled with c-Fos and either enkephalin or 5-HT were found more frequently in all thr

225 receptor-deficient or lacking either pre-pro-enkephalin or beta-endorphin.

226 phalin (DAMGO) or morphine] or DOR (D-Pen(5)-enkephalin or SNC80) agonists increased RGS19 and GIPC p

227 c medium spiny neurons that expressed either enkephalin or substance P and extended fibers to the glo

228 ouble-labeled with c-Fos and beta-endorphin, enkephalin or VGLUT3 in the ARC were significantly incre

229 lization of dynorphin (or prodynorphin) with enkephalin (or Phe-Arg-Met-enkephalin).

230 10(-5) M naltrexone (NTX), 10(-5) M [Met(5)]-enkephalin, or sterile vehicle was administered to one e

231 ls and synthesis of the orexigenic peptides, enkephalin, orexin and melanin-concentrating hormone, as

232 be presented for [(eta(6)-Cp*Rh-Tyr(1))-leu-enkephalin](OTf)(2) and [(eta(6)-Cp*Rh-Tyr(3))-octreotid

233 iatum, which expresses the endogenous opioid enkephalin, patches (or striosomes) are limbic-associate

234 protease cathepsin L for producing the (Met)enkephalin peptide neurotransmitter from proenkephalin (

235 YR, and GsYR), to more biologically relevant enkephalin peptides (YGGFL, pYGGFL, and sYGGFL).

236 We found that ILC2s produce methionine-enkephalin peptides that can act directly on adipocytes

237 abolic homeostasis in part via production of enkephalin peptides that elicit beiging.

238 In situ Met/Leu-enkephalin peptides were expressed in differentiating ke

239 Enkephalins play a major role in reproductive physiology

240 In particular, the endogenous opioid enkephalin plays a significant role in regulating amygda

241 ice, PDE10A content selectively increases in enkephalin-positive striatal neuronal bodies; moreover,

242 Together, substance P- and enkephalin-positive terminals represent 24% of all synap

243 urons containing preprotachykinin and prepro-enkephalin (PPE) mRNAs were also activated, with the non

244 is entailed the solid-phase synthesis of two enkephalin precursor chains followed by a Cu(I)-catalyze

245 ne expression, leading to an upregulation of enkephalin precursor Penk mRNA and met-enkephalin protei

246 Under these conditions, leucine-enkephalin present at concentrations as low as 125nM was

247 of the presynaptic delta-opioid receptor by enkephalin prevents the increase in neuronal Na(V)1.7 in

248 and related findings, we suggest endogenous enkephalins primarily set a background motivational tone

249 neutral antagonist 6beta-naltrexol; (2) pro-enkephalin, pro-opiomelanocortin, and pro-dynorphin KO m

250 or agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)]-enkephalin produces paradoxical behavioural responses: e

251 Vector-mediated enkephalin production in vivo prevented the increase in

252 The therapeutic potential of reducing enkephalin production or signaling merits further explor

253 we used viral vectors utilizing dynorphin or enkephalin promoters to drive expression of 5-HT6 recept

254 on of enkephalin precursor Penk mRNA and met-enkephalin protein in sensory neurons.

255 In contrast, the levels of phospholipase A2, enkephalin, PSD-95, synaptophysin, or glutamate NMDA rec

256 method is illustrated by using a set of four enkephalin-related and acetylated peptides to generate 1

257 ype regulates MOR function by modulating met-enkephalin release.

258 olesterol restored [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin responses back to control values, and were co

259 inhibition of neprilysin alone could enhance enkephalin responses to the same extent as inhibitors of

260 in highly increased cellular levels of (Met)enkephalin, resulting from the conversion of PE to enkep

261 ors to determine which peptidase(s) regulate enkephalin signaling in this region.

262 The enkephalin signaling pathway regulates various neural fu

263 /or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by receptor bin

264 er, desensitization of D-Ala(2)-Met(5)-Glyol-enkephalin-stimulated [(35)S]GTPgammaS binding following

265 emonstrated by reduced D-Ala(2)-Met(5)-Glyol-enkephalin-stimulated [(35)S]GTPgammaS binding to spinal

266 Enkephalin suppresses inhibition onto striatal projectio

267 micro-domain within dorsal neostriatum where enkephalin surges are triggered by the opportunity to co

268 Here, we provide evidence that enkephalin surges in an anteromedial quadrant of dorsal

269 Endogenous >150% enkephalin surges in anterior dorsomedial neostriatum we

270 PENK is a stable surrogate analyte of labile enkephalins that is correlated inversely with renal func

271 GF) is an endogenous opioid peptide ([Met(5)]enkephalin) that interacts with the OGF receptor (OGFr)

272 roach, we have electroosmotically pulled Leu-enkephalin through OHSCs to identify ectopeptidase activ

273 lized with dynorphin, oxytocin, vasopressin, enkephalin, thyrothropin-releasing hormone, and corticot

274 mu-opioid agonist [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin to acutely inhibit adenylyl cyclase or to cau

275 lthough not affecting the ability of [Met](5)enkephalin to induce desensitization, acutely reversed t

276 is study clearly demonstrates the ability of enkephalins to disrupt insect sexual development and als

277 aine-trained mice, indicating that increased enkephalin tone on presynaptic mu opioid receptors was r

278 Gamma-aminobutyric acid (GABA) and enkephalin tonically inhibit neurons within the RVLM.

279 r prodrug - tyrosinyl(1)palmitate-leucine(5)-enkephalin (TPLENK) were coated with the polymer - N-pal

280 mportant GPCR peptides; namely, [Tyr(1)]-leu-enkephalin, [Tyr(4)]-neurotensin(8-13), and [Tyr(3)]-oct

281 nerve ligation is accompanied by D1R and met-enkephalin upregulation, acquired D1LR-mediated antinoci

282 ory cells that coexpress beta-endorphin, Met-enkephalin, uroguanylin, and Trpm5 exist in mouse duoden

283 Quantitative determination of leu-enkephalin using external calibration was verified by st

284 ate release by a submaximal concentration of enkephalin was doubled by application of all three pepti

285 opioid peptide [d-Ala(2),N-MePhe(4),Gly-ol]-enkephalin was not reversed by ethanol.

286 ally in close proximity to fibers containing enkephalin was noted in the NAmb of EA-treated cats (n=5

287 A standard curve of Leu-enkephalin was performed in the presence of a background

288 The opioid receptor agonist, leu-enkephalin, was predicted to have antisurvival effects i

289 erivatization conditions for 1microM leucine-enkephalin were achieved when 10mM cysteine and 200U/ml

290 While perikarya containing enkephalin were observed in some medullary nuclei (e.g.,

291 ymes, which increases the synaptic levels of enkephalins) were enhanced in BAMBI-KO mice.

292 An antibody against Phe-Arg-Met-enkephalin, which did not recognize Leu- and Met-enkepha

293 In tyrosyl-glycine and Leu-enkephalin, which have N-terminal tyrosines, bicyclic in

294 thalamic levels of the endogenous opioid Leu-enkephalin, which is derived from the KOR agonist precur

295 R signaling resulting from lowered levels of enkephalins, which is partly mediated through elevated e

296 n of the opioid growth factor (OGF) [Met(5)]-enkephalin with its receptor (OGFr) is a regulator of TC

297 se results indicate increased levels of (Met)enkephalin within secretory vesicles of the regulated se

298 ed in neurons containing the opioid peptide, enkephalin, within the dorsolateral striatum.

299 morphine and DAMGO (D-Ala2-N-Me-Phe4-glycol5-enkephalin) without affecting agonist potency, the onset

300 nated C-terminally methyl esterified leucine enkephalin [YGGFL-OMe+H](+).